![Mark Edbrooke](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Edbrooke
Corporate Officer/Principal chez
THALIA THERAPEUTICS PLC
Profil
Mark Edbrooke has held roles at Thalia Therapeutics Plc starting in 2025 as Head-Strategy and at Argonaute RNA Ltd. as Head-Translational Research.
Both positions are current.
Postes actifs de Mark Edbrooke
| Sociétés | Poste | Début |
|---|---|---|
| THALIA THERAPEUTICS PLC | Corporate Officer/Principal | 27/05/2025 |
Argonaute RNA Ltd.
 Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Develops safe and reliable methods of temporarily silencing target genes in different tissue cells | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
14
Relations au 1er degré
2
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
N4 Pharma Plc
 N4 Pharma Plc BiotechnologyHealth Technology Provides specialist pharmaceutical services that reformulates existing drugs and vaccines to improve their performance | Health Technology |
Argonaute RNA Ltd.
Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Develops safe and reliable methods of temporarily silencing target genes in different tissue cells | Commercial Services |
